History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: Post hoc analysis from a placebo-controlled study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 5, 2008, Pages 368-375

  Marks, David M ^a   Han, Changsu ^a   Krulewicz, Stan ^b   Pae, Chi Un ^a   Peindl, Kathleen ^a   Patkar, Ashwin A ^a   Masand, Prakash S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; IBU TAB; IBUPROFEN; NAPROXEN; PAROXETINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; IRRITABLE COLON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL STRESS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PREDICTOR VARIABLE; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; STRUCTURED INTERVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 54349100467     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v10n0504     Document Type: Article

References (46)

1. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-654
2. Garakani A, Win T, Virk S, et al. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003;10:61-67
3. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-2146
4. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993 Sep;38(9):1569-1580
5. Reilly J, Baker GA, Rhodes J, et al. The association of sexual and physical abuse with somatization: characteristics of patients presenting with irritable bowel syndrome and non-epileptic attack disorder. Psychol Med 1999;29:399-406
6. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med 1999 Nov;107(5A):65S-73S
7. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122(4):1140-1156
8. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001;62(suppl 8):28-36
9. Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001;62(suppl 8):38-45
10. Folks DG. The interface of psychiatry and irritable bowel syndrome. Curr Psychiatry Rep 2004;6(3):210-215
11. Dinan TG, O'Keane V, O'Boyle C, et al. A comparison of the mental status, personality profiles and life events of patients with irritable bowel syndrome and peptic ulcer disease. Acta Psychiatr Scand 1991;84:26-28
12. Dancey CP, Taghavi M, Fox RJ: The relationship between daily stress and symptoms of irritable bowel: a time-series approach. J Psychosom Res 1998;44:537-545
13. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-833
14. Talley NJ, Fett SL, Zinsmeister AR. Self-reported abuse and gastrointestinal disease in outpatients: association with irritable bowel-type symptoms. Am J Gastroenterol 1995;90:366-371
15. Sullivan G, Jenkins PL, Blewett AE. Irritable bowel syndrome and family history of psychiatric disorder: a preliminary study. Gen Hosp Psychiatry 1995;17(1):43-46
16. Hudson JI, Mangweth B, Pope HG Jr, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003;60(2):170-177
17. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48:272-282
18. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-147
19. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72
20. Hudson JI, Pope HG Jr. The concept of affective spectrum disorder: relationship to fibromyalgia and other syndromes of chronic fatigue and chronic muscle pain. Baillieres Clin Rheumatol 1994;8(4):839-856
21. Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry 2002 Feb;4(1):12-16
22. Kato O, Misawa H. Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Prim Care Companion J Clin Psychiatry 2005;7(4):202
23. Masand PS, Gupta S, Schwartz TL, et al. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005;7(4):162-166
24. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-920
25. Creed F, Guthrie E, Ratcliffe J, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry 2005;39:807-815
26. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103
27. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-228
28. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-385
29. Thompson W, Longstreth G, Drossman D. Functional bowel disorders and functional abdominal pain. In: Drossman D, Talley NJ, Thompson WG, et al, eds. Rome II. The Functional Gastrointestinal Disorders, vol 2. 2nd ed. McLean, Va: Degnon Associates; 2000:351-432
30. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131
31. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
32. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
33. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897
34. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-9643
35. Kobak KA, Taylor LH, Dottl SL, et al. A computer-administered telephone interview to identify mental disorders. JAMA 1997;278:905-910
36. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222
37. Karling P, Danielsson A, Adolfsson R, et al. No difference in symptoms of irritable bowel syndrome between healthy subjects and patients with recurrent depression in remission. Neurogastroenterol Motil 2007 Nov;19(11):896-904
38. Lackner JM, Quigley BM, Blanchard EB. Depression and abdominal pain in IBS patients: the mediating role of catastrophizing. Psychosom Med 2004;66(3):435-441
39. Sayuk GS, Elwing JE, Lustman PJ, et al. Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders. Psychosom Med 2007 Feb-Mar;69(2):173-181
40. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984
41. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
42. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982-1988
43. Maddock RJ, Carter CS, Blacker KH, et al. Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. J Clin Psychiatry 1993 Mar;54(3):88-95
44. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 1997 Dec;58(12):555-561
45. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
46. Minocha A, Chad W, Do W, et al. Racial differences in epidemiology of irritable bowel syndrome alone, uninvestigated dyspepsia alone, and "overlap syndrome" among African Americans compared to Caucasians: a population-based study. Dig Dis Sci 2006;51:218-226